Ligand Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ligand Pharmaceuticals (LGND).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$302Upside to Avg. PT-4.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	Barclays	Glen Santangelo	Initiate	Overweight	$345
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$358
Sep 23, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$390→$397
Aug 14, 2026	Leerink Partners	David Risinger	Initiate	Outperform	$330
Aug 7, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$340→$345
Aug 6, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$289→$358
Aug 3, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$285→$326
Jul 21, 2026	Citigroup	Yigal Nochomovitz	Reinstates	Buy	$387
Jul 15, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$262→$340
Jul 9, 2026	B of A Securities	Jason Zemansky	PT Raise	Buy	$266→$388
Jul 8, 2026	Stifel	Annabel Samimy	PT Raise	Buy	$255→$332
May 8, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$252→$262
Apr 30, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$243→$289
Apr 28, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$235→$252
Apr 15, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$276→$282
Apr 14, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$239→$243
Mar 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$270→$276
Mar 11, 2026	B of A Securities	Jason Zemansky	Initiate	Buy	$244
Feb 27, 2026	Oppenheimer	Trevor Allred	PT Raise	Outperform	$275→$277
Feb 24, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$231→$239

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.

Benzinga Newsdesk

Ligand Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Ligand Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

People Also Watch

People Also Watch

Ligand Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Ligand Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PROHC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PROCitigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PROLeerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRORBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PROHC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358